Cme (CME) EBIT (2009 - 2026)

Cme (CME) has 18 years of EBIT data on file, last reported at $1.3 billion in Q1 2026.

• EBIT for Q1 2026 came in at $1.3 billion, up 18.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 billion (up 8.61% YoY), and the FY2025 annual result was $4.2 billion, up 7.58% from the prior year.
• EBIT grew to $1.3 billion in Q1 2026 per CME's latest filing, from $1.0 billion in the prior quarter.
• Over five years, EBIT peaked at $1.3 billion in Q1 2026 and troughed at $668.3 million in Q4 2022.
• A 5-year average of $936.6 million and a median of $947.1 million in 2024 frame the typical range for EBIT.
• The sharpest annual moves came in 2023 and 2025: EBIT increased 29.16% in 2023, then fell 5.04% in 2025.
• A 5-year view of EBIT shows it stood at $668.3 million in 2022, then gained by 29.16% to $863.2 million in 2023, then climbed by 9.72% to $947.1 million in 2024, then grew by 7.65% to $1.0 billion in 2025, then advanced by 28.45% to $1.3 billion in 2026.
• Business Quant data shows CME's EBIT at $1.3 billion in Q1 2026, $1.0 billion in Q4 2025, and $972.6 million in Q3 2025.